Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

NCT ID: NCT02268279

Last Updated: 2017-06-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pediatric study to evaluate the safety and pharmacokinetics of solithromycin (oral and intravenous) in children ages 0 to 17

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

solithromycin

oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day

Group Type EXPERIMENTAL

solithromycin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

solithromycin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CEM-101

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Suspected or confirmed bacterial infection with organisms against which solithromycin is expected to be active.

Exclusion Criteria

* Serum creatinine \>2 mg/dL
* Positive pregnancy test in females of childbearing potential
* History of intolerance or hypersensitivity to macrolide antibiotics
Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Department of Health and Human Services

FED

Sponsor Role collaborator

Melinta Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Cohen-Wolkowiez, MD

Role: PRINCIPAL_INVESTIGATOR

Duke Clinical Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Little Rock, Arkansas, United States

Site Status

Orange, California, United States

Site Status

Palo Alto, California, United States

Site Status

San Diego, California, United States

Site Status

Jacksonville, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Chicago, Illinois, United States

Site Status

Iowa City, Iowa, United States

Site Status

Wichita, Kansas, United States

Site Status

Louisville, Kentucky, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

St Louis, Missouri, United States

Site Status

Omaha, Nebraska, United States

Site Status

Hackensack, New Jersey, United States

Site Status

Albuquerque, New Mexico, United States

Site Status

Albany, New York, United States

Site Status

Brooklyn, New York, United States

Site Status

Chapel Hill, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Portland, Oregon, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Splendora, Texas, United States

Site Status

Richmond, Virginia, United States

Site Status

Seattle, Washington, United States

Site Status

Morgantown, West Virginia, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Plovdiv, , Bulgaria

Site Status

Rousse, , Bulgaria

Site Status

Sofia, , Bulgaria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria

References

Explore related publications, articles, or registry entries linked to this study.

Beechinor RJ, Cohen-Wolkowiez M, Jasion T, Hornik CP, Lang JE, Hernandez R, Gonzalez D. A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication. Ther Drug Monit. 2019 Dec;41(6):761-765. doi: 10.1097/FTD.0000000000000670.

Reference Type DERIVED
PMID: 31318840 (View on PubMed)

Gonzalez D, James LP, Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, Benjamin DK Jr, Cohen-Wolkowiez M. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00692-18. doi: 10.1128/AAC.00692-18. Print 2018 Aug.

Reference Type DERIVED
PMID: 29891609 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CE01-120

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Safety and PK Study of IV Eravacycline
NCT03696550 COMPLETED PHASE1
TELI TON - Telithromycin in Tonsillitis
NCT00315042 TERMINATED PHASE3